Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review
DOI:
https://doi.org/10.12775/JEHS.2025.81.66740Keywords
esketamine, treatment-resistant depression, suicidal ideation, NMDA receptor, ketamineAbstract
Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work. Esketamine offers rapid symptom reduction through NMDA receptor antagonism.
Aim. To systematically review current evidence on efficacy and safety of esketamine nasal spray in treating depression with active suicidal ideation and treatment-resistant depression, focusing on rapidity of response and clinical outcomes.
Material and methods. PubMed search using terms "esketamine, depression, suicide" and related. After screening, 11 studies from 2020 onwards were analyzed.
Results. ASPIRE II showed esketamine 84mg superior to placebo at 24 hours: MADRS reduction -15.7 vs -12.4 points (p=0.006), with effects at 4 hours. In 456 patients, response rates were 34.5% vs 25.3%, remission 20.4% vs 9.8% at 24 hours. Versus quetiapine, esketamine achieved 27.1% vs 17.6% remission at week 8 (p=0.003). Long-term data (1,148 patients, 31.5 months) showed suicide attempts 0.361 and deaths 0.036 per 100 patient-years. Common side effects: dizziness (38-47%), nausea (27-33%), transient dissociation; 4-11% discontinued treatment.
Conclusions. Esketamine demonstrates rapid efficacy in reducing depressive symptoms and suicidal ideation, with effects within hours and sustained benefits. It shows superior results versus placebo and comparators with acceptable safety, making it valuable for acute suicidal ideation requiring rapid intervention.
References
Caliman-Fontes, A. T., Leal, G. C., Correia-Melo, F. S., Paixao, C. S., Carvalho, M. S., Jesus-Nunes, A. P., Vieira, F., Magnavita, G., Bandeira, I. D., Mello, R. P., Beanes, G., Silva, S. S., Echegaray, M., Carvalho, L. P., Machado, P., Sampaio, A. S., Cardoso, T. de A., Kapczinski, F., Lacerda, A. L. T., & Quarantini, L. C. (2023). Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends in Psychiatry and Psychotherapy, 45. https://doi.org/10.47626/2237-6089-2021-0298
Canuso, C. M., Ionescu, D. F., Li, X., Qiu, X., Lane, R., Turkoz, I., Nash, A. I., Lopena, T. J., & Fu, D. J. (2021). Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. Journal of Clinical Psychopharmacology, 41(5), 516–524. https://doi.org/10.1097/JCP.0000000000001465
Czora-Poczwardowska, K., Kujawski, R., Jaworska, J., Mikołajczak, P., & Szulc, M. (2024). A review of the antidepressant effects of esketamine and arketamine in treatment-resistant depression. Pharmacotherapy in Psychiatry and Neurology, 40(2), 127–142. https://doi.org/10.5114/fpn.2024.147494
Daly, E. J., Turkoz, I., Salvadore, G., Fedgchin, M., Ionescu, D. F., Starr, H. L., Borentain, S., Trivedi, M. H., Thase, M. E., & Singh, J. B. (2021). The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depression and Anxiety, 38(11), 1120–1130. https://doi.org/10.1002/da.23193
Degerlund Maldi, K., Asellus, P., Myléus, A., & Norström, F. (2021). Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression. BMC Psychiatry, 21(1). https://doi.org/10.1186/s12888-021-03601-8
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023). The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis. Revista Da Associacao Medica Brasileira, 69(4). https://doi.org/10.1590/1806-9282.2023D694
Fu, D. J., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O'Hara, M., & Canuso, C. M. (2023). Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry, 23(1). https://doi.org/10.1186/s12888-023-05017-y
Höflich, A., Kraus, C., Pfeiffer, R. M., Seiger, R., Rujescu, D., Zarate, C. A., Kasper, S., Winkler, D., & Lanzenberger, R. (2021). Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. Translational Psychiatry, 11(1). https://doi.org/10.1038/s41398-021-01318-6
Ionescu, D. F., Fu, D. J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021). Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). International Journal of Neuropsychopharmacology, 24(1), 22–31. https://doi.org/10.1093/ijnp/pyaa068
Jha, M. K., Williamson, D. J., Magharehabed, G., Turkoz, I., Daly, E. J., & Trivedi, M. H. (2023). Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. Journal of Affective Disorders, 321, 153–160. https://doi.org/10.1016/j.jad.2022.10.020
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024). Esketamine in depression: putative biomarkers from clinical research. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01865-1
Katz, E. G., Hough, D., Doherty, T., Lane, R., Singh, J., & Levitan, B. (2021). Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clinical Pharmacology and Therapeutics, 109(2), 536–546. https://doi.org/10.1002/cpt.2024
Kawczak, P., Feszak, I., & Bączek, T. (2024). Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms. Biomedicines, 12(10). https://doi.org/10.3390/biomedicines12102283
Kosik-Gonzalez, C., Fu, D.-J., Nancy Chen, L., Lane, R., Bloch, M. H., DelBello, M., Moreno, C., Drevets, W. C., & Canuso, C. M. (n.d.). Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. https://doi.org/10.1016/j.jaac.2025.02.015
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology, 49(1), 41–50. https://doi.org/10.1038/s41386-023-01629-w
Lan, X., Wang, C., Zhang, F., Liu, H., Li, W., Ye, Y., Hu, Z., Mai, S., Ning, Y., & Zhou, Y. (2023). Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial. Child and Adolescent Psychiatry and Mental Health, 17(1). https://doi.org/10.1186/s13034-023-00647-2
McIntyre, R. S., Bitter, I., Buyze, J., Fagiolini, A., Godinov, Y., Gorwood, P., Ito, T., Oliveira-Maia, A. J., Vieta, E., Werner-Kiechle, T., Young, A. H., & Reif, A. (2024). Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. European Neuropsychopharmacology, 85, 58–65. https://doi.org/10.1016/j.euroneuro.2024.05.009
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. v., Jaramillo, C. L., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., … Stahl, S. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383–399. https://doi.org/10.1176/appi.ajp.2020.20081251
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. v., Frye, M. A., Zarate, C. A., & Goes, F. S. (2022). Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Molecular Psychiatry, 27(9), 3658–3669. https://doi.org/10.1038/s41380-022-01652-1
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023). Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review. Pharmaceuticals, 16(4). https://doi.org/10.3390/ph16040634
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024). Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review. International Journal of Molecular Sciences, 25(23). https://doi.org/10.3390/ijms252313098
Pardossi, S., Fagiolini, A., Scheggi, S., & Cuomo, A. (2024). A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope? Children, 11(7). https://doi.org/10.3390/children11070801
Pompili, M. (2020). Intranasal Esketamine and Current Suicidal Ideation With Intent in Major Depression Disorder: Beat the Clock, Save a Life, Start a Strategy. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00325
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y. (2023). Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine, 389(14), 1298–1309. https://doi.org/10.1056/nejmoa2304145
Rizzo, A., Garçon-Poca, M. Z., Essmann, A., Souza, A. J., Michaelides, M., Ciruela, F., & Bonaventura, J. (2025). The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors. Molecular Psychiatry, 30(8), 3443–3454. https://doi.org/10.1038/s41380-025-02931-3
Ross, E. L., & Soeteman, D. I. (2020). Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the united states. Psychiatric Services, 71(10), 988–997. https://doi.org/10.1176/APPI.PS.201900625
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020). Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Therapeutic Advances in Drug Safety, 11. https://doi.org/10.1177/2042098620937899
Turkoz, I., Lopena, O., Salvadore, G., Sanacora, G., Shelton, R., & Fu, D. J. (2023). Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: A pooled post hoc analysis of ASPIRE. CNS Spectrums, 28(4), 482–488. https://doi.org/10.1017/S1092852922000931
Vasiliu, O. (2023). Esketamine for treatment‑resistant depression: A review of clinical evidence (Review). Experimental and Therapeutic Medicine, 25(3). https://doi.org/10.3892/etm.2023.11810
Vieira, F., Correia-Melo, F. S., Santos-Lima, C., Souza-Marques, B., Leal, G. C., Jesus-Nunes, A. P., Mello, R. P., Caliman-Fontes, A. T., Bandeira, I. D., Marback, R. F., Telles, M., Argolo, F. C., Lins-Silva, D. H., Echegaray, M. V. F., Beanes, G., Araújo-de-Freitas, L., Silva, S. S., Cardoso, T. de A., Kapczinski, F., … Quarantini, L. C. (2021). Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial. General Hospital Psychiatry, 68, 97–99. https://doi.org/10.1016/j.genhosppsych.2020.12.011
Yang, S., Wang, J., Li, X., Wang, T., Xu, Z., Xu, X., Zhou, X., & Chen, G. (2022). Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials. Psychiatric Quarterly, 93(1), 81–95. https://doi.org/10.1007/s11126-020-09871-x
Zaki, N., Chen, L. (Nancy), Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D. J. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology, 48(8), 1225–1233. https://doi.org/10.1038/s41386-023-01577-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Natalia Dudziak, Zuzanna Drozd, Bartosz Niemiec, Szymon Piosik, Bruno Olesiński, Łukasz Piasecki, Zuzanna Guzowicz, Monika Kamińska, Patrycja Gągałka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 101
Number of citations: 0
